Neuroendocrine Neoplasm: Current Understanding

Overview

Journal J Postgrad Med

Specialty General Medicine

Date 2023 Mar 24

PMID 36960525

Authors

A R Lila

S S Memon

Affiliations

Soon will be listed here.

References

Goroshi M, Bandgar T, Lila A, Jadhav S, Khare S, Shrikhande S . Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India. Fam Cancer. 2016; 15(4):617-24. DOI: 10.1007/s10689-016-9891-7. View

Goroshi M, Jadhav S, Lila A, Kasaliwal R, Khare S, Yerawar C . Comparison of 68Ga-DOTANOC PET/CT and contrast-enhanced CT in localisation of tumours in ectopic ACTH syndrome. Endocr Connect. 2016; 5(2):83-91. PMC: 5002954. DOI: 10.1530/EC-16-0010. View

Rindi G, Klimstra D, Abedi-Ardekani B, Asa S, Bosman F, Brambilla E . A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018; 31(12):1770-1786. PMC: 6265262. DOI: 10.1038/s41379-018-0110-y. View

Anlauf M, Garbrecht N, Bauersfeld J, Schmitt A, Henopp T, Komminoth P . Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch. 2007; 451 Suppl 1:S29-38. DOI: 10.1007/s00428-007-0450-3. View

Formica V, Wotherspoon A, Cunningham D, Norman A, Sirohi B, Oates J . The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer. 2007; 96(8):1178-82. PMC: 2360161. DOI: 10.1038/sj.bjc.6603699. View

Shah R, Garg R, Majmundar M, Purandare N, Malhotra G, Patil V . Exendin-4-based imaging in insulinoma localization: Systematic review and meta-analysis. Clin Endocrinol (Oxf). 2021; 95(2):354-364. DOI: 10.1111/cen.14406. View

Kaltsas G, Michael Besser G, Grossman A . The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004; 25(3):458-511. DOI: 10.1210/er.2003-0014. View

Hofland J, Herrera-Martinez A, Zandee W, de Herder W . Management of carcinoid syndrome: a systematic review and meta-analysis. Endocr Relat Cancer. 2019; 26(3):R145-R156. DOI: 10.1530/ERC-18-0495. View

Hofland J, Zandee W, de Herder W . Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol. 2018; 14(11):656-669. DOI: 10.1038/s41574-018-0082-5. View

10.

Palepu J, Shrikhande S, Bhaduri D, Shah R, Sirohi B, Chhabra V . Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: A report of multicenter data from a web-based registry. Indian J Gastroenterol. 2018; 36(6):445-451. DOI: 10.1007/s12664-017-0808-7. View

11.

Lomte N, Kumar S, Sarathi V, Pandit R, Goroshi M, Jadhav S . Genotype phenotype correlation in Asian Indian von Hippel-Lindau (VHL) syndrome patients with pheochromocytoma/paraganglioma. Fam Cancer. 2017; 17(3):441-449. DOI: 10.1007/s10689-017-0058-y. View

12.

Grahame-Smith D . Progress report: the carcinoid syndrome. Gut. 1970; 11(2):189-92. PMC: 1411352. DOI: 10.1136/gut.11.2.189. View

13.

Ballal S, Yadav M, Bal C, Sahoo R, Tripathi M . Broadening horizons with Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2019; 47(4):934-946. DOI: 10.1007/s00259-019-04567-2. View

14.

Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress T . Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology. 2016; 104(1):26-32. DOI: 10.1159/000443612. View

15.

de Herder W, Lamberts S . Clinical endocrinology and metabolism. Gut endocrine tumours. Best Pract Res Clin Endocrinol Metab. 2004; 18(4):477-95. DOI: 10.1016/j.beem.2004.08.003. View

16.

Herrera-Martinez A, Hofland J, Hofland L, Brabander T, Eskens F, Galvez Moreno M . Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs. 2018; 79(1):21-42. PMC: 6338796. DOI: 10.1007/s40265-018-1033-0. View

17.

Marotta V, Zatelli M, Sciammarella C, Ambrosio M, Bondanelli M, Colao A . Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocr Relat Cancer. 2017; 25(1):R11-R29. DOI: 10.1530/ERC-17-0269. View

18.

Patil V, Goroshi M, Shah H, Malhotra G, Hira P, Sarathi V . Comparison of Ga-DOTA-NaI-Octreotide/tyr-octreotate positron emission tomography/computed tomography and contrast-enhanced computed tomography in localization of tumors in multiple endocrine neoplasia 1 syndrome. World J Nucl Med. 2020; 19(2):99-105. PMC: 7478292. DOI: 10.4103/wjnm.WJNM_24_19. View

19.

Hofland J, Feelders R, Brabander T, Franssen G, de Herder W . Recent developments in the diagnosis and therapy of well-differentiated neuroendocrine tumours. Neth J Med. 2018; 76(3):100-108. View

20.

Hicks R, Kwekkeboom D, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R . ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology. 2017; 105(3):295-309. DOI: 10.1159/000475526. View